ALKERMES | ALKS - Resultado Líquido





Resultado Líquido Alterar Data
AbbVie USD 4.22B 605M 2026-09
Acadia Pharmaceuticals USD 53.52M 22.02M 2026-09
ALKERMES USD 16.29M 15.79M 2026-09
Amgen USD 3.86B 1.49B 2026-09
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD -122.83M 167.59M 2026-09
Bristol-Myers Squibb USD 2.16B 1.16B 2026-09
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.1B 301M 2026-06
Gilead Sciences USD -10.5B 12.52B 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -87M 27.65M 2026-09
J&J USD 210M 5.32B 2026-09
Malin Corporation EUR -1.1M 2.2M 2023-12
Merck USD 5.07B 6.4B 2026-09
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 206.5M 62.1M 2026-09
Otsuka Holdings JPY 106.49B 10.77B 2026-09
Ovoca Bio EUR 4.42M 5.19M 2025-12
Pfizer USD 3.24B 3.49B 2026-09
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Vertex Pharmaceuticals USD 653.6M 446.2M 2026-09